查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
特发性肺纤维化市场－全球与区域分析、区域分析与预测（2025-2035）
市场调查报告书
商品编码
1818892

特发性肺纤维化市场－全球与区域分析、区域分析与预测（2025-2035）

Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

全球特发性肺纤维化市场 - 分析与预测（2025-2035）

特发性肺纤维化 (IPF) 是进行性性肺部疾病，其特征是肺组织逐渐瘢痕化（纤维化），损害肺部正常运作的能力。

「特发性」是指确切病因尚不清楚，但据信是由遗传和环境因素共同作用所致。在特发性肺纤维化（IPF）中，纤维组织的形成会导致肺部僵硬，从而引发呼吸困难，尤其是在运动时。

随着病情进展，瘢痕形成范围会扩大，进一步限制血液中的氧气输送。特发性肺纤维化 (IPF) 的症状包括呼吸急促、持续干咳、疲劳和不明原因的体重减轻。虽然病情进展因人而异，但目前尚无治疗方法，治疗方法重点在于控制症状和减缓病情进展。早期诊断和医疗介入对于改善 IPF 患者的生活品质和延长生存期至关重要。

特发性肺纤维化 (IPF) 的高盛行率是推动治疗方法和治疗方案研发的关键驱动力。该疾病主要影响老年人，由于人口老化和公众对该疾病的认识提高，全球确诊病例正在增加。不断增长的患者群体对有效治疗方法和新型治疗方案的需求很大。随着越来越多的患者被诊断出患有特发性肺纤维化 (IPF)，製药公司和医疗保健提供者积极应对与这种进行性且通常致命的疾病相关的未满足医疗需求。盛行率越高，投资研发以提高生存率和生活品质就越重要。

活性化研发活动是推动 IPF 治疗进步的关键驱动力之一。研究人员正在努力了解导致 IPF 的遗传、分子和环境因素，以帮助开发更有针对性和更有效的治疗方法。随着我们对 IPF 的了解不断加深，重点正转向精准医疗，这可以根据每个人的基因特征来客製化治疗方案。研发工作也正致力于改善药物输送系统、优化现有治疗方法以及探索可以解决纤维化根本原因的新型药物。这种对研发的加强重视加速了创新，从而发现了候选药物，并使得能够开发出为患者带来更好结果的治疗方法。活性化研发也促进了跨产业合作，使研究人员、製药公司和医疗保健组织能够应对 IPF 带来的挑战。

然而，儘管成长前景光明，特发性肺纤维化市场仍面临挑战。一个主要障碍是有效治疗方案有限。虽然有几种核准的抗纤维化疗法，如Pirfenidone和尼达尼布，但这些治疗方法主要旨在减缓疾病进展，而不是逆转它。此外，这些治疗方法并非对所有患者都有效，目前的选择只针对症状，而不是 IPF 的根本原因。 IPF 目前尚无治癒治疗方法，缺乏替代治疗方法给患者和医疗保健系统带来了沉重的负担。治疗方法有限，再加上大多数现有治疗方法只能减缓而不是预防疾病进展，限制了疾病的整体管理。这是市场面临的一个主要限制因素，因为市场迫切需要更有效的疾病修正治疗。

全球特发性肺纤维化市场竞争激烈，许多主要企业推动技术创新和市场成长。霍夫曼罗氏有限公司、Pliant Therapeutics, Inc.、百时美施贵宝、Vicore Pharma AB 和 Pliant Therapeutics, Inc. 等公司处于开发和商业化特发性肺纤维化 (IPF) 治疗方案的前沿。这些公司正在大力投资开发下一代治疗方法，包括标靶治疗治疗、生物製剂和创新药物传递系统，以加强其在特发性肺纤维化 (IPF) 治疗的市场地位。他们正在改进目前的抗纤维化疗法，扩大肺移植选择，并探索可能减缓疾病进展和逆转肺损伤的新方法。此外，这些公司正在进行大规模临床试验，以评估新治疗方法的有效性、安全性和长期益处，努力更好地了解 IPF 的潜在机制并提供新的、更有效的治疗方法。透过与学术和研究机构建立策略伙伴关係和合作，我们旨在加速开发突破性治疗方法，改善患者的治疗效果，并为受这种危及生命的疾病影响的人们带来希望。

市场区隔

细分1：按地区

  • 北美洲
  • 欧洲
  • 亚太地区

鑑于目前可用的治疗方法有限，製药公司拥有重大机会来开发针对特发性肺纤维化（IPF）根本病因而非仅控制其症状的新型治疗方法。基因疗法、干细胞疗法、个人化医疗和先进生技药品等创新疗法有望提供更具针对性和有效性的治疗方案。这些治疗方法专注于在基因或分子层面逆转或阻止纤维化过程，有望显着改善患者的预后和生活品质。随着我们对特发性肺纤维化（IPF）遗传和分子机制的理解不断加深，发现能够改变IPF病程的突破性治疗方法，将带来宝贵的市场机会。

目录

执行摘要

第 1 章全球特发性肺纤维化市场：产业分析

  • 市场概况与生态系统
  • 流行病学分析
  • 主要市场趋势
    • 影响分析
  • 监管状况
  • 管道分析
  • 市场动态
    • 概述
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球特发性肺纤维化市场（按地区）及价值，2023-2035年

  • 北美洲
    • 市场动态
    • 市场规模及预测
    • 2023-2035年北美特发性肺纤维化市场（百万美元）
  • 欧洲
    • 市场动态
    • 市场规模及预测
    • 欧洲特发性肺纤维化市场（百万美元）按国家划分，2023-2035 年
  • 亚太地区
    • 市场动态
    • 市场规模及预测
    • 2023-2035年亚太地区特发性肺纤维化市场（百万美元）

第三章：竞争格局与公司概况

  • 竞争格局
  • 公司简介
    • Hoffmann-La Roche Ltd.
    • Boehringer Ingelheim Pharma GmbH & Co. KG
    • Pliant Therapeutics, Inc.
    • Vicore Pharma AB
    • Kadmon Corporation, LLCs
    • Bristol-Myers Squibb
    • PureTech
    • Nitto Denko Corporation
    • Bridge Biotherapeutics, Inc.
    • Galecto Biotech
    • Tvardi Therapeutics, Incorporated.
    • Galecto Biotech
    • 其他的

第四章调查方法

Product Code: BHL3271SA

Global Idiopathic Pulmonary Fibrosis Market, Analysis and Forecast: 2025-2035

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by the gradual scarring (fibrosis) of lung tissue, which impairs the ability of the lungs to function properly. The term "idiopathic" means that the exact cause of the disease is unknown, though it is believed to result from a combination of genetic and environmental factors. In IPF, the lungs become stiff due to the formation of fibrous tissue, leading to difficulty in breathing, especially during physical activity.

As the disease advances, the scarring becomes more extensive, further limiting the oxygen supply to the bloodstream. Symptoms of IPF include shortness of breath, a persistent dry cough, fatigue, and unexplained weight loss. The progression of the disease varies among individuals, but there is currently no cure, and treatments focus on managing symptoms and slowing the disease's progression. Early diagnosis and medical intervention are crucial to improving the quality of life and extending survival in patients with IPF.

The high prevalence of IPF has become a significant driver for the development of therapies and treatment solutions. The disease primarily affects older adults, with an increasing number of diagnosed cases globally due to an aging population and improved awareness of the condition. This growing patient population creates a substantial demand for effective treatments and new therapeutic options. As more people are diagnosed with IPF, pharmaceutical companies and healthcare providers are motivated to address the unmet medical needs associated with this progressive and often fatal disease. The higher the prevalence, the more essential it becomes to invest in research and the development of therapies that can improve survival rates and quality of life.

Increasing R&D activities are one of the key drivers for the advancement of IPF treatments. Researchers are working to uncover the genetic, molecular, and environmental factors that contribute to the disease, helping to develop more targeted and effective therapies. As the understanding of IPF deepens, the focus is shifting toward precision medicine, where treatments can be tailored to individual genetic profiles. R&D efforts are also being directed at improving drug delivery systems, optimizing existing therapies, and exploring new classes of drugs that can address the underlying causes of fibrosis. This heightened focus on R&D accelerates innovation, leads to the discovery of new drug candidates, and enables the development of treatment regimens that can provide better results for patients. Increased R&D also promotes collaboration across industries, bringing together researchers, pharmaceutical companies, and healthcare institutions to tackle the challenges posed by IPF.

However, despite the promising growth prospects, challenges remain in the idiopathic pulmonary fibrosis market. A major hurdle is the limited number of effective treatment options available. While there are a few approved antifibrotic therapies, such as pirfenidone and nintedanib, these treatments primarily aim to slow the progression of the disease rather than reverse it. Additionally, these therapies may not be effective for all patients, and the current options only address the symptoms, not the root cause of IPF. There is no known cure for IPF, and the lack of alternative treatment options places a considerable burden on patients and healthcare systems. The limited availability of therapies, coupled with the fact that most current treatments can only delay disease progression rather than prevent it, restricts the overall management of the disease. This is a major restraint in the market as there is a critical need for more effective, disease-modifying therapies.

The global idiopathic pulmonary fibrosis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., Bristol-Myers Squibb, Vicore Pharma AB, and Pliant Therapeutics, Inc., are at the forefront of developing and commercializing treatment options for idiopathic pulmonary fibrosis. These companies are investing significantly in the development of next-generation therapies, including targeted treatments, biologic therapies, and innovative drug delivery systems to strengthen their market position in the treatment of idiopathic pulmonary fibrosis (IPF). By focusing on improving current antifibrotic therapies, enhancing lung transplantation options, and exploring novel approaches aim to slow disease progression and potentially reverse lung damage. Additionally, these companies are conducting extensive clinical trials to evaluate the efficacy, safety, and long-term benefits of emerging therapies, striving to better understand the underlying mechanisms of IPF and offer new, more effective treatment alternatives. Through strategic partnerships and collaboration with academic institutions and research organizations, they aim to accelerate the development of breakthrough therapies that can improve patient outcomes and provide hope for individuals affected by this life-threatening condition.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

With limited treatment options currently available, there is a substantial opportunity for pharmaceutical companies to develop novel therapies that address the underlying causes of IPF, rather than just managing its symptoms. Innovative therapeutic approaches such as gene therapy, stem cell therapy, personalized medicine, and advanced biologics have the potential to offer more targeted and effective treatments. By focusing on reversing or halting the fibrosis process at the genetic or molecular level, these therapies could significantly improve patient outcomes and quality of life. As researchers continue to uncover the genetic and molecular mechanisms of IPF, the potential for discovering breakthrough treatments that could alter the course of the disease becomes a valuable market opportunity.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Idiopathic Pulmonary Fibrosis Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Idiopathic Pulmonary Fibrosis Market (by Region), Value ($Million), 2023-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, by Country ($Million), 2023-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Hoffmann-La Roche Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Boehringer Ingelheim Pharma GmbH & Co. KG
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Pliant Therapeutics, Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Vicore Pharma AB
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Kadmon Corporation, LLCs
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Bristol-Myers Squibb
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 PureTech
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Nitto Denko Corporation
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Bridge Biotherapeutics, Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Galecto Biotech
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Tvardi Therapeutics, Incorporated.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Galecto Biotech
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Others

4. Research Methodology

List of Figures

  • Figure: Global Idiopathic Pulmonary Fibrosis Market Coverage
  • Figure: Global Idiopathic Pulmonary Fibrosis Market Key Trends, Impact Analysis, 2023-2035

List of Tables

  • Table: Global Idiopathic Pulmonary Fibrosis Market Dynamics, Impact Analysis
  • Table: Global Idiopathic Pulmonary Fibrosis Market (by Region), $Million, 2023-2035